This is a multicenter prospective study to develop and validate a multimodal, deep learning-based model for predicting treatment response in patients with extranodal natural killer/T-cell lymphoma (NKTCL) receiving first-line asparaginase-based therapy.
1. Age ≥ 18 years.
2. Pathologically confirmed extranodal natural killer/T-cell lymphoma (NKTCL) according to the World Health Organization (WHO) classification.
3. Patients who are planned to receive first-line asparaginase-based chemotherapy or chemoradiotherapy.
4. Patients who have either contrast-enhanced MRI of the nasopharynx obtained as part of routine clinical care or pretreatment whole-slide images (WSI) of tumor tissue from hematoxylin and eosin (H&E)-stained sections available for analysis.
1. History of other malignant tumors.
2. Patients with psychiatric disorders or those unable to provide informed consent.